Recent News
CAR T cell therapy took the centre stage in 2022 where data pertaining to a successful case series of 5 patients with refractory SLE were published by Prof Schett’s group. Since then, this area of therapeutic has expanded exponentially. Our growing enthusiasm was slightly dampened though when the FDA required all six approved CAR T-cell therapies in oncology to include a black box warning regarding the risk of second primary malignancies in January 2024. At ACR25, Prof Schett’s group described a new form of toxicity in patients with autoimmune disease receiving CAR T-cell therapy, most likely due to the cleansing of immune cells from the affected organs.Read Article
Deucravacitinib and Renal Function: Insights from the PAISLEY Trial
In the phase 2 PAISLEY trial, deucravacitinib met its primary and secondary endpoints, demonstrating efficacy across multiple clinical and patient-reported outcomes. However, the impact on renal function has remained unclear. An abstract presented at ACR provides new insights.
Read Article
PET Uptake in Large Vessel GCA – Does tocilizumab help?
Giant cell arteritis (GCA) is the most common form of adult vasculitis in the United States and can be subdivided into those with cranial only symptoms, those with large vessel vasculiti/PMR, and those with mixed features. Non-invasive imaging is key in detecting large vessel involvement in GCA, as many of these patients do not experience signs or symptoms specific to this vascular disease (i.e.
Read Article
The Decade Ahead: Predicting Long-Term Proteinuria Risk in SLE
Lupus nephritis affects almost half of patients with SLE and conveys a mortality rate of up to 30% at 10 years, with at least 10-22% of patients developing end-stage kidney disease. Early detection and diagnosis are https://t.co/ggoA2KsqXg
Dr. John Cush @RheumNow ( View Tweet)
Belimumab Before or After Immunosuppressant
Dr. Yuz Yusof reports on abstract 0803 presented at #ACR25
https://t.co/BVFhDDfTvW https://t.co/F9ZvGXIqVn
Dr. John Cush @RheumNow ( View Tweet)
Using AI and LLMs in Qualitative Data
Dr. Bella Mehta discusses abstract 0794 (Using AI to Analyze Multilingual Qualitative Data in Lupus Pregnancy Research: A Proof of Concept with Large Language Models) presented at #ACR25
https://t.co/HFBuNxdZOF https://t.co/gKAXURq8xR
Dr. John Cush @RheumNow ( View Tweet)
If We Can’t Prevent RA, Can We at Least Prevent Difficult-to-Treat RA?
Despite major advances in RA management, some patients develop difficult-to-treat RA (D2TRA), characterized by ongoing inflammation and impairment despite multiple therapies. While understanding of the https://t.co/FcF0V82KdT
Dr. John Cush @RheumNow ( View Tweet)
What should head-to-head studies in inflammatory arthritis teach us?
The multimillion dollar question for inflammatory arthritis prescriptions is: which drug should I use next?
Read Article
The Long View of Diagnostic Delay in Axial Spondyloarthritis
At #ACR25, Abstract #1407 presented a cross-sectional analysis from the Brazilian Spondyloarthritis Registry (RBE), offering a unique perspective on how diagnostic patterns have evolved over six decades. https://t.co/7ttYXJtfpc
Dr. John Cush @RheumNow ( View Tweet)
#ACR25 – Day 2 Report
Here are 3 abstracts that caught my eye on Day 2 at #ACR25. Notably these have takeaway messages that should support your current practices.
https://t.co/xKPAgeWudD https://t.co/Fb16l6A252
Links:
Dr. John Cush @RheumNow ( View Tweet)
Cellular Biomarkers of Rheumatoid Arthritis
Dr. Jeffrey Sparks reports on four abstracts at #ACR25.
https://t.co/ZO259DXIcW https://t.co/HOpgiXfYvM
Dr. John Cush @RheumNow ( View Tweet)
PsA: Impact of Sex
Dr. Arthur Kavanaugh highlights the importance of sex on disease characteristics and response to therapy in psoriatic arthritis, reporting from #ACR25.
https://t.co/QtU4iATexR https://t.co/uCJsxYpFTc
Dr. John Cush @RheumNow ( View Tweet)
Nerandomilast for ILD
Dr. Mike Putman reports on abstract 1662 (Efficacy and Safety of Nerandomilast in Patients with Autoimmune Disease-Related Progressive Pulmonary Fibrosis: Subgroup Analysis of the FIBRONEER-ILD trial). #ACR25
https://t.co/J0e4SbVgFE https://t.co/dlOM700yVQ
Dr. John Cush @RheumNow ( View Tweet)
#ACR25 Best Abstracts - Day 2
After a full day at the Chicago Convention center the RheumNow faculty have posted some of their favorite reports included these that they labeled as being the "best' of day 2.
https://t.co/gyIWQXVJ50 https://t.co/vjlK41hzFD
Links:
Dr. John Cush @RheumNow ( View Tweet)
Are we putting the CAR-T before the horse?
CAR T-cells have been a revolutionary development in rheumatology. We have seen a population of patients with severe refractory autoimmune conditions almost overnight presented with the prospect of not just improvement, but of a cure. https://t.co/niPU5cAojP
Dr. John Cush @RheumNow ( View Tweet)
Marketscan claims study of 62,813 IMID women w/ 70,529 pregnancies & 69,412 births, 4,485 (7.1%) were exposed to at least one TNFi during pregnancy & 3,559 postpartum. TNFi use NOT assoc w/ SIE risk during Preg (HR 1.39; 0.95-2.05) or postpartum (HR 1.22; https://t.co/NsxOLpT0ds
Dr. John Cush @RheumNow ( View Tweet)
💬 #ACR25 Topic Panels — LIVE!
Nov. 5 join RheumNow at 7 PM ET for a deep dives into the hottest topics in rheumatology:
👉 SpA
Join Us Live on:
X • Facebook • YouTube • LinkedIn • https://t.co/V10S4oVFsv
Top experts. Real clinical insight. Don't miss these discussions https://t.co/ARrEpN2ybC
Links:
Dr. John Cush @RheumNow ( View Tweet)
GLP-1 and SGLT-2: Treatments Too Good to Ignore?
Dr. Peter Nash reviews several studies presented on GLP-1s at #ACR25. He recommends for review abstracts: 0841, 0849, 1027, 2685, 0165, 0233 and 2658.
https://t.co/OclO05bpku https://t.co/kASID9jnAP
Dr. John Cush @RheumNow ( View Tweet)
B Cell Depletion: Check the Lymph Node
Dr. Akhil Sood reports on abstract 2695 (B-cell depletion and lymphoid follicle disruption upon different B-cell depleting agents) presented at #ACR25.
https://t.co/BjgIC3Kng0 https://t.co/flfyLZYW8q
Dr. John Cush @RheumNow ( View Tweet)
From the blog
Podcasts
ACR 2025 SpA Topic Panel
ACR 2025 CAR-T Topic Panel
ACR 2025 RA Topic Panel
ACR 2025 PsA Topic Panel
Therapeutic Updates
Sjögren’s Disease – What Are You Missing?
Sponsored by Novartis Pharmaceuticals Corporation
What could you be missing in Sjögren's disease? Explore hypothetical patient cases with atypical presentations, systemic manifestations, and overlooked symptoms. Gain expert insights and practical tips for clinical assessment from Dr Shereen Mahmood and learn how the ESSDAI can help you measure disease activity.
Read Post
A JAKi in GCA: Phase 3 Results Through 2 Years
Sponsored by AbbVie Medical Affairs + Health Impact
Listen as rheumatologists Dr. Anisha Dua and Dr. Ben Boone discuss the latest efficacy and safety results over 2 years from a Phase 3 trial in GCA, including remission, flares, and glucocorticoid use in patients continuing vs withdrawing a JAKi"
Read Post
Poster Hall
